Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease. 
In the metastatic setting, major advances include the incorporation of 
immunotherapy and targeted therapies into the clinician's therapeutic 
armamentarium. Standard chemotherapeutic regimens have long been reported to 
interfere with the immune response to the tumor; conversely, antitumor immunity 
may add to the effects of those therapies. The aim of immunotherapy is to 
specifically enhance the immune response directed to the tumor. Recently, many 
trials addressed the role of such therapies for metastatic NSCLC treatment: 
ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic 
agents of main interest in this field. In addition, anti-tumor vaccines, such as 
MAGE-A3, Tecetomide, TG4010, CIMAvax, ganglioside vaccines, tumor cell vaccines 
and dendritic cell vaccines, emerged as potent inducers of immune response 
against the tumor. The current work aims to address the most recent developments 
regarding these innovative immunotherapies and their implementation in the 
treatment of metastatic NSCLC.